Propanc Biopharma Provides A Shareholder Update for 2021
MELBOURNE, Australia--(BUSINESS WIRE)--
Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that its Chief Executive Officer, Mr James Nathanielsz, provides a shareholder update for 2021 as business confidence increases, spurred on by a post pandemic recovery as vaccines are rolled out across the globe. A combination of easing of lockdown restrictions has led to improving economic conditions, supported by government incentives over the last 12 months since the beginning of the pandemic. After experiencing some of the harshest lockdown conditions in the world last year as a result of the COVID-19 pandemic in Australia, Propanc intends to seize advantage of the hard work undertaken recently with its capital restructure, scientific research activities and “cash back benefits” to be received from the Australian government.